CN107835690A - 通过t细胞疗法治疗埃巴病毒相关淋巴细胞增生性病症的方法 - Google Patents

通过t细胞疗法治疗埃巴病毒相关淋巴细胞增生性病症的方法 Download PDF

Info

Publication number
CN107835690A
CN107835690A CN201680039509.4A CN201680039509A CN107835690A CN 107835690 A CN107835690 A CN 107835690A CN 201680039509 A CN201680039509 A CN 201680039509A CN 107835690 A CN107835690 A CN 107835690A
Authority
CN
China
Prior art keywords
allogeneic
ebv
cells
lpd
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680039509.4A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·约翰·奥莱利
苏珊·伊丽莎白·普罗科普
艾莎·纳斯林·哈桑
E·道布罗维纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56027234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107835690(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN107835690A publication Critical patent/CN107835690A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680039509.4A 2015-05-12 2016-05-11 通过t细胞疗法治疗埃巴病毒相关淋巴细胞增生性病症的方法 Pending CN107835690A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160549P 2015-05-12 2015-05-12
US62/160,549 2015-05-12
PCT/US2016/031784 WO2016183153A1 (en) 2015-05-12 2016-05-11 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Publications (1)

Publication Number Publication Date
CN107835690A true CN107835690A (zh) 2018-03-23

Family

ID=56027234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680039509.4A Pending CN107835690A (zh) 2015-05-12 2016-05-11 通过t细胞疗法治疗埃巴病毒相关淋巴细胞增生性病症的方法

Country Status (18)

Country Link
US (1) US10568908B2 (https=)
EP (1) EP3294304B1 (https=)
JP (2) JP7284556B2 (https=)
KR (1) KR102666781B1 (https=)
CN (1) CN107835690A (https=)
AR (1) AR104598A1 (https=)
AU (1) AU2016262484B2 (https=)
BR (1) BR112017024431B1 (https=)
CA (1) CA2984178C (https=)
CL (1) CL2017002846A1 (https=)
FR (1) FR23C1025I2 (https=)
IL (1) IL255581B (https=)
MX (1) MX386334B (https=)
NZ (1) NZ736675A (https=)
PH (1) PH12017501993A1 (https=)
RU (1) RU2720245C2 (https=)
WO (1) WO2016183153A1 (https=)
ZA (1) ZA201707335B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981413A (zh) * 2019-10-23 2022-08-30 昆士兰医学研究所理事会 过继免疫治疗
CN118256604A (zh) * 2024-04-16 2024-06-28 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ749136A (en) 2016-05-25 2023-11-24 Council Queensland Inst Medical Res Methods of immunotherapy
AU2017326173B2 (en) * 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells
AU2018355145A1 (en) * 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
US20200350049A1 (en) * 2018-01-08 2020-11-05 Atara Biotherapeutics, Inc. Systems and methods for distributing cell therapies
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003773A1 (en) * 1997-07-10 2000-05-31 The Council Of The Queensland Institute Of Medical Research Ctl epitopes from ebv
CN104394877A (zh) * 2012-05-08 2015-03-04 约翰·霍普金斯大学 用于输注短暂植入的同种异体淋巴细胞的选定群体来治疗癌症的方法和组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
EP2365823B1 (en) 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
AU2011295845B2 (en) 2010-09-01 2016-09-22 Baylor College Of Medicine EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC)
CA2889064A1 (en) * 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
JP2016539929A (ja) * 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
MY189857A (en) * 2014-11-05 2022-03-14 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003773A1 (en) * 1997-07-10 2000-05-31 The Council Of The Queensland Institute Of Medical Research Ctl epitopes from ebv
CN104394877A (zh) * 2012-05-08 2015-03-04 约翰·霍普金斯大学 用于输注短暂植入的同种异体淋巴细胞的选定群体来治疗癌症的方法和组合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
D.T.铃木等: "《遗传分析导论》", 31 August 1990, 陕西人民教育出版社 *
EKATERINA DOUBROVINA等: "Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV lymphomas after allogeneic hematopoietic cell transplantation", 《BLOOD》 *
RAJIV KHANNA等: "Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease", 《PNAS》 *
TANZINA HAQUE等: "Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells", 《THE LANCET》 *
陈育民: "《病原生物学与免疫学》", 30 January 2011, 第四军医大学出版社 *
顾长海: "《传染病学新进展 第2卷》", 30 November 1990, 科学技术文献出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981413A (zh) * 2019-10-23 2022-08-30 昆士兰医学研究所理事会 过继免疫治疗
CN118256604A (zh) * 2024-04-16 2024-06-28 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Also Published As

Publication number Publication date
MX2017014257A (es) 2018-04-20
US10568908B2 (en) 2020-02-25
CA2984178C (en) 2023-10-31
BR112017024431B1 (pt) 2021-10-13
KR102666781B1 (ko) 2024-05-20
MX386334B (es) 2025-03-18
US20180125891A1 (en) 2018-05-10
RU2017143151A (ru) 2019-06-13
HK1244697A1 (en) 2018-08-17
JP2018520095A (ja) 2018-07-26
EP3294304A1 (en) 2018-03-21
CL2017002846A1 (es) 2018-05-25
RU2720245C2 (ru) 2020-04-28
AR104598A1 (es) 2017-08-02
ZA201707335B (en) 2021-02-24
IL255581B (en) 2021-03-25
KR20180003575A (ko) 2018-01-09
JP2021119154A (ja) 2021-08-12
RU2017143151A3 (https=) 2019-10-29
AU2016262484A1 (en) 2018-01-04
NZ736675A (en) 2023-03-31
IL255581A (en) 2018-01-31
CA2984178A1 (en) 2016-11-17
AU2016262484B2 (en) 2021-10-21
PH12017501993A1 (en) 2018-03-26
WO2016183153A1 (en) 2016-11-17
JP7284556B2 (ja) 2023-05-31
FR23C1025I1 (fr) 2023-07-21
EP3294304B1 (en) 2020-01-29
FR23C1025I2 (fr) 2025-04-18
BR112017024431A2 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
CN107835690A (zh) 通过t细胞疗法治疗埃巴病毒相关淋巴细胞增生性病症的方法
EP3490605B1 (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
ES2949664T3 (es) Inhibidores PD-1/PD-L1
TW202104252A (zh) 用於生產car-nk細胞之方法及其用途
JP2020530277A (ja) 反復投与のための細胞免疫療法
JP2021500878A (ja) 免疫療法のためのｔ細胞受容体
TWI759270B (zh) 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法
US20220378890A1 (en) Immunogenic egfr peptide compositions and their use in the treatment of cancer
US20250249098A1 (en) Cryopreservation of nk cell products for off-the-shelf immunotherapy
US20220372092A1 (en) Hla-restricted vcx/y peptides and t cell receptors and use thereof
HK1244697B (en) Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
HK40008076A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
HK40008076B (en) Replacement of cytotoxic preconditioning before cellular immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination